DP
INDV icon

Diadema Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Diadema Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-220,300
Closed -$7.9M – 170
2025
Q4 		$7.9M Buy
+220,300
New +$6.73M 1.36% 24

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Diadema Partners's INDV Position: Q2 2026 in Review

Diadema Partners reduced its Indivior Pharmaceuticals (INDV) stake by 5.4% in Q2 2026, selling an estimated $140K and leaving 67,512 shares worth $2.77M. The position accounts for 0.35% of the portfolio, ranked #65.

Diadema Partners first reported a position in INDV in Q3 2025 and has held it in 4 quarters since. The position peaked at $6.13M in Q3 2025. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Diadema Partners held 67,512 shares of Indivior Pharmaceuticals worth $2.77M as of Q2 2026.
  • Diadema Partners sold 3,864 Indivior Pharmaceuticals shares in Q2 2026, an estimated $140K.
  • Indivior Pharmaceuticals made up 0.35% of Diadema Partners's portfolio in Q2 2026, its #65 holding.
  • Diadema Partners first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Diadema Partners's Indivior Pharmaceuticals position peaked at $6.13M in Q3 2025.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.